×
News Home

Do Analysts Agree on CymaBay Therapeutics Inc (CBAY) Stock's Target Price?

Wednesday, February 17, 2021 01:30 PM | InvestorsObserver Analysts
Do Analysts Agree on CymaBay Therapeutics Inc (CBAY) Stock's Target Price?

Wall Street is positive on CymaBay Therapeutics Inc (CBAY). On average, analysts give CymaBay Therapeutics Inc a Strong Buy rating. The average price target is $12.909, which means analysts expect the stock to rise by 134.28% over the next twelve months.

That average ranking earns CymaBay Therapeutics Inc an Analyst Rating of 78, which is better than 78% of stocks based on data compiled by InvestorsObserver.

Overall Score - 5
Wall Street analysts are rating CBAY a Strong Buy today. Find out what this means to you and get the rest of the rankings on CBAY!

Why are Analyst Ratings Important?

Analysts know the inner workings of the companies they follow better than anyone but the companies’ management. You can learn a lot about a company from studying the financial statements, but analysts ask questions on conference calls and understand the intricacies of each of the businesses they cover. Analysts understand how bad weather in one part of the world can disrupt supply chains, or disrupt shopping patterns. This lets traders make decisions before a quarterly report that could be worse than expected.

InvestorsObserver aggregates the ratings of all the analysts covering a given stock, takes the average of those ratings and then percentile ranks the averages. That provides a level of granularity that is significantly better than just the three levels provided by traditional buy/hold/sell ratings.

What's Happening With CymaBay Therapeutics Inc Stock Today?

CymaBay Therapeutics Inc (CBAY) stock is trading at $5.51 as of 1:12 PM on Wednesday, Feb 17, a loss of -$0.12, or -2.22% from the previous closing price of $5.63. The stock has traded between $5.40 and $5.60 so far today. Volume today is 965,625 compared to average volume of 1,247,770.

Click Here to get the full report on CymaBay Therapeutics Inc (CBAY) Stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App